SURMOUNT-4

CompletedPhase 3Results posted

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)

Lead sponsor

Eli Lilly and Company

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

Recruiting sites

—

Enrollment

783

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04660643

Org study ID17247

Secondary IDI8F-MC-GPHNEli Lilly and Company

Timeline

Milestones

Study first posted2020-12-09actual

Study start2021-03-29actual

Primary completion2023-04-25actual

Study completion2023-05-18actual

Last update posted2024-05-22actual

Results first posted2024-05-22actual

Assets

Investigational agents

Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Body Mass Index (BMI) ≥30 kilograms per square meter (kg/m²), or ≥27 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease

•History of at least one unsuccessful dietary effort to lose body weight

Exclusion criteria

•Diabetes mellitus

•Change in body weight greater than 5 kg within 3 months prior to starting study

•Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity

•History of pancreatitis

•Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)

•History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years

•Any lifetime history of a suicide attempt

Endpoints (52)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Glycemic / diabetes

Cardiometabolic biomarkers

Patient-reported / QoL

Weight & body composition

24 endpoints

Primary/registry result

Percent Change From Randomization in Body Weight at Week 88

Time frame:Randomization (Week 36), Week 88

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percent change	95% CI
Placebo	14.8	—
Tirzepatide MTD	-6.7	—

LS Mean difference-21.495% CI-22.9 – -20.0p<.001Mixed Models Analysis

Primary/protocol endpoint

Percent Change From Randomization in Body Weight at Week 88

Time frame:Randomization (Week 36), Week 88

Body weight, % change

percent change from baseline, improvement

Secondary/registry result

Percent Change From Randomization in Body Weight at Week 64

Time frame:Randomization (Week 36), Week 64

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percent change	95% CI
Placebo	9.9	—
Tirzepatide MTD	-6.0	—

LS Mean difference-15.995% CI-17.0 – -14.9p<.001Mixed Models Analysis

Secondary/registry result

Change From Randomization in Body Weight

Time frame:Randomization (Week 36), Week 88

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilogram (kg)	95% CI
Placebo	11.9	—
Tirzepatide MTD	-5.7	—

LS Mean difference-17.695% CI-18.8 – -16.4p<.001Mixed Models Analysis

Secondary/registry result

Change From Randomization in Waist Circumference

Time frame:Randomization (Week 36), Week 88

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), centimetre (cm)	95% CI
Placebo	8.3	—
Tirzepatide MTD	-4.6	—

LS Mean difference-12.995% CI-14.1 – -11.7p<.001Mixed Models Analysis

Secondary/registry result

Change From Randomization in Body Mass Index (BMI)

Time frame:Randomization (Week 36), Week 88

BMI, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kilogram per square metre (kg/m^2)	95% CI
Placebo	4.3	—
Tirzepatide MTD	-2.1	—

LS Mean difference-6.495% CI-6.8 – -6.0p<.001Mixed Models Analysis

Secondary/registry result

Percentage of Participants Who Maintain at Least 80% of the Body Weight Lost During the Open-Label Lead-In Period

Time frame:Week 88

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo	13.50	—
Tirzepatide MTD	93.37	—

Odds Ratio (OR)95.9195% CI54.72 – 168.09p<0.001Regression, Logistic

Secondary/registry result

Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline

Time frame:Baseline (Week 0) to Week 88

≥20% weight-loss responders

threshold achievement, improvement

Posted result

Group	Value (number), percentage of participants	95% CI
Placebo≥5% body weight reduction from baseline	69.00	—
≥10% body weight reduction from baseline	44.38	—
≥15% body weight reduction from baseline	24.01	—
≥20% body weight reduction from baseline	11.55	—
Tirzepatide MTD≥5% body weight reduction from baseline	98.49	—
≥10% body weight reduction from baseline	93.98	—
≥15% body weight reduction from baseline	87.05	—
≥20% body weight reduction from baseline	72.59	—

Odds Ratio (OR)47.2795% CI18.32 – 121.99p<0.001Regression, Logistic

≥5% body weight reduction from baseline

Odds Ratio (OR)71.5195% CI34.46 – 148.39p<0.001Regression, Logistic

≥10% body weight reduction from baseline

Odds Ratio (OR)79.9995% CI42.06 – 152.14p<0.001Regression, Logistic

≥15% body weight reduction from baseline

Odds Ratio (OR)140.8495% CI66.06 – 300.29p<0.001Regression, Logistic

≥20% body weight reduction from baseline

Secondary/registry result

Time to First Occurrence of Participants Returning to >95% Baseline Weight for Those Who Lost ≥5% During the Open-Label Lead-In Period

Time frame:Randomization (Week 36) to Week 88

time to event, event

Posted result

Group	Value (median), weeks	95% CI
Placebo	NA	NA – NA
Tirzepatide MTD	NA	NA – NA

Hazard Ratio (HR)0.01395% CI0.004 – 0.046p<.001Log Rank

Secondary/registry result

Change From Baseline in BMI

Time frame:Baseline (Week 0), Week 88

BMI, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kg/m^2	95% CI
Placebo	-3.6	—
Tirzepatide MTD	-10.0	—

LS Mean difference-6.495% CI-6.8 – -6.0p<.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Body Weight

Time frame:Baseline (Week 0), Week 88

Body weight, absolute change (kg)

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), kg	95% CI
Placebo	-10.0	—
Tirzepatide MTD	-27.6	—

LS Mean difference-17.695% CI-18.8 – -16.4p<.001Mixed Models Analysis

Secondary/registry result

Percent Change From Baseline in Body Weight

Time frame:Baseline (Week 0), Week 88

Body weight, % change

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percent change	95% CI
Placebo	-9.5	—
Tirzepatide MTD	-26.0	—

LS Mean difference-16.495% CI-17.5 – -15.4p<.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Waist Circumference

Time frame:Baseline (Week 0), Week 88

Waist circumference, change

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), cm	95% CI
Placebo	-9.1	—
Tirzepatide MTD	-22.8	—

LS Mean difference-13.695% CI-15.1 – -12.2p<.001Mixed Models Analysis

Secondary/protocol endpoint

Percent Change From Randomization in Body Weight at Week 64

Time frame:Randomization (Week 36), Week 64

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change From Randomization in Body Weight

Time frame:Randomization (Week 36), Week 88

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Change From Randomization in Waist Circumference

Time frame:Randomization (Week 36), Week 88

Waist circumference, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Randomization in Body Mass Index (BMI)

Time frame:Randomization (Week 36), Week 88

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Who Maintain at Least 80% of the Body Weight Lost During the Open-Label Lead-In Period

Time frame:Week 88

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, ≥20% Body Weight Reduction From Baseline

Time frame:Baseline (Week 0) to Week 88

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Time to First Occurrence of Participants Returning to >95% Baseline Weight for Those Who Lost ≥5% During the Open-Label Lead-In Period

Time frame:Randomization (Week 36) to Week 88

time to event, event

Secondary/protocol endpoint

Change From Baseline in BMI

Time frame:Baseline (Week 0), Week 88

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Body Weight

Time frame:Baseline (Week 0), Week 88

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Percent Change From Baseline in Body Weight

Time frame:Baseline (Week 0), Week 88

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Waist Circumference

Time frame:Baseline (Week 0), Week 88

Waist circumference, change

change from baseline, improvement

Glycemic / diabetes

12 endpoints

Secondary/registry result

Change From Randomization in Fasting Glucose

Time frame:Randomization (Week 36), Week 88

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), milligrams per deciliter (mg/dL)	95% CI
Placebo	7.74	—
Tirzepatide MTD	-0.90	—

LS Mean difference-8.6495% CI-10.14 – -7.15p<.001Mixed Models Analysis

Secondary/registry result

Change From Randomization in Hemoglobin A1c (HbA1c)

Time frame:Randomization (Week 36), Week 88

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), percentage of HbA1c	95% CI
Placebo	0.25	—
Tirzepatide MTD	-0.08	—

LS Mean difference-0.3395% CI-0.38 – -0.28p<.001Mixed Models Analysis

Secondary/registry result

Percent Change From Randomization in Fasting Insulin

Time frame:Randomization (Week 36), Week 88

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percent change	95% CI
Placebo	23.3	—
Tirzepatide MTD	-15.4	—

LS Mean difference-31.495% CI-37.7 – -24.4p<.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in Fasting Glucose

Time frame:Baseline (Week 0), Week 88

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Posted result

Group	Value (least_squares_mean), mg/dL	95% CI
Placebo	-1.72	—
Tirzepatide MTD	-10.63	—

LS Mean difference-8.9295% CI-10.40 – -7.43p<.001Mixed Models Analysis

Secondary/registry result

Change From Baseline in HbA1c

Time frame:Baseline (Week 0), Week 88

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Posted result

Group	Value (least_squares_mean), percentage of HbA1c	95% CI
Placebo	-0.22	—
Tirzepatide MTD	-0.57	—

LS Mean difference-0.3495% CI-0.39 – -0.29p<.001Mixed Models Analysis

Secondary/registry result

Percent Change From Baseline in Fasting Insulin

Time frame:Baseline (Week 0), Week 88

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percent change	95% CI
Placebo	-29.8	—
Tirzepatide MTD	-54.1	—

LS Mean difference-34.695% CI-40.6 – -27.9p<.001Mixed Models Analysis

Secondary/protocol endpoint

Change From Randomization in Fasting Glucose

Time frame:Randomization (Week 36), Week 88

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change From Randomization in Hemoglobin A1c (HbA1c)

Time frame:Randomization (Week 36), Week 88

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percent Change From Randomization in Fasting Insulin

Time frame:Randomization (Week 36), Week 88

percent change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in Fasting Glucose

Time frame:Baseline (Week 0), Week 88

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Secondary/protocol endpoint

Change From Baseline in HbA1c

Time frame:Baseline (Week 0), Week 88

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Percent Change From Baseline in Fasting Insulin

Time frame:Baseline (Week 0), Week 88

percent change from baseline, improvement

Cardiometabolic biomarkers

8 endpoints

Secondary/registry result

Percent Change From Randomization in Lipid Parameters (Total Cholesterol, Low Density Lipoprotein (LDL) Cholesterol, High Density Lipoprotein (HDL) Cholesterol, Very Low Density Lipoprotein (VLDL) Cholesterol, Triglycerides, Free Fatty Acids (FFA))

Time frame:Randomization (Week 36), Week 88

percent change from baseline, improvement

componentsTotal cholesterol, change, LDL-C, change, HDL-C, change, VLDL, change, Triglycerides, change, Free fatty acids, change

Posted result

Group	Value (least_squares_mean), percent change	95% CI
PlaceboTotal Cholesterol	8.30	—
LDL Cholesterol	3.43	—
HDL Cholesterol	14.6	—
VLDL Cholesterol	14.7	—
Triglycerides	15.6	—
FFA	-2.9	—
Tirzepatide MTDTotal Cholesterol	2.29	—
LDL Cholesterol	-3.36	—
HDL Cholesterol	18.3	—
VLDL Cholesterol	-7.8	—
Triglycerides	-8.2	—
FFA	-13.4	—

LS Mean difference-5.5495% CI-7.76 – -3.28p<.001Mixed Models Analysis

Total Cholesterol

LS Mean difference-6.5795% CI-9.87 – -3.15p<.001Mixed Models Analysis

LDL Cholesterol

LS Mean difference3.295% CI0.6 – 5.8p0.014Mixed Models Analysis

HDL Cholesterol

LS Mean difference-19.795% CI-24.0 – -15.1p<.001Mixed Models Analysis

VLDL Cholesterol

LS Mean difference-20.695% CI-24.9 – -16p<.001Mixed Models Analysis

Triglycerides

LS Mean difference-10.895% CI-17.9 – -3.0p0.008Mixed Models Analysis

FFA

Secondary/registry result

Change From Randomization in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)

Time frame:Randomization (Week 36), Week 88

change from baseline, improvement

componentsSystolic BP, change, Diastolic BP, change

Posted result

Group	Value (least_squares_mean), millimetre of mercury (mmHg)	95% CI
PlaceboSBP	8.4	—
DBP	3.2	—
Tirzepatide MTDSBP	2.1	—
DBP	-0.4	—

LS Mean difference-6.495% CI-8.1 – -4.6p<.001Mixed Models Analysis

SBP

LS Mean difference-3.695% CI-4.8 – -2.4p<.001Mixed Models Analysis

DBP

Secondary/registry result

Percent Change From Baseline in Lipid Parameters (Total Cholesterol, LDL Cholesterol, HDL Cholesterol, VLDL Cholesterol, Triglycerides, FFAs)

Time frame:Baseline (Week 0), Week 88

percent change from baseline, improvement

Posted result

Group	Value (least_squares_mean), percent change	95% CI
PlaceboTotal Cholesterol	2.16	—
LDL Cholesterol	2.62	—
HDL Cholesterol	9.44	—
VLDL Cholesterol	-15.6	—
Triglycerides	-15.3	—
FFA	-9.69	—
Tirzepatide MTDTotal Cholesterol	-5.01	—
LDL Cholesterol	-5.21	—
HDL Cholesterol	12.29	—
VLDL Cholesterol	-32.6	—
Triglycerides	-33.3	—
FFA	-20.38	—

LS Mean difference-7.0295% CI-9.27 – -4.72p<.001Mixed Models Analysis

Total Cholesterol

LS Mean difference-7.6295% CI-10.91 – -4.21p<.001Mixed Models Analysis

LDL Cholesterol

LS Mean difference2.6095% CI-0.14 – 5.43p0.064Mixed Models Analysis

HDL Cholesterol

LS Mean difference-20.195% CI-24.7 – -15.3p<.001Mixed Models Analysis

VLDL Cholesterol

LS Mean difference-21.295% CI-25.8 – -16.4p<.001Mixed Models Analysis

Triglycerides

LS Mean difference-11.8395% CI-18.98 – -4.06p0.004Mixed Models Analysis

FFA

Secondary/registry result

Change From Baseline in SBP, DBP

Time frame:Baseline (Week 0), Week 88

Systolic BP, change

change from baseline, improvement

LOINC 8480-6

Posted result

Group	Value (least_squares_mean), mmHg	95% CI
PlaceboSBP	-2.4	—
DBP	-1.7	—
Tirzepatide MTDSBP	-9.3	—
DBP	-5.5	—

LS Mean difference-6.995% CI-8.7 – -5.1p<.001Mixed Models Analysis

SBP

LS Mean difference-3.895% CI-5.1 – -2.6p<.001Mixed Models Analysis

DBP

Secondary/protocol endpoint

Time frame:Randomization (Week 36), Week 88

percent change from baseline, improvement

Secondary/protocol endpoint

Change From Randomization in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP)

Time frame:Randomization (Week 36), Week 88

change from baseline, improvement

componentsSystolic BP, change, Diastolic BP, change

Secondary/protocol endpoint

Percent Change From Baseline in Lipid Parameters (Total Cholesterol, LDL Cholesterol, HDL Cholesterol, VLDL Cholesterol, Triglycerides, FFAs)

Time frame:Baseline (Week 0), Week 88

percent change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in SBP, DBP

Time frame:Baseline (Week 0), Week 88

change from baseline, improvement

componentsSystolic BP, change, Diastolic BP, change

Patient-reported / QoL

8 endpoints

Secondary/registry result

Change From Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form - Physical Functioning Domain Score

Time frame:Randomization (Week 36), Week 88

SF-36 physical

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), T-score	95% CI
Placebo	-1.8	—
Tirzepatide MTD	0.8	—

LS Mean difference2.695% CI1.7 – 3.5p<.001ANCOVA

Secondary/registry result

Change From Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Function Composite Score

Time frame:Randomization (Week 36), Week 88

IWQOL-Lite physical

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), score on a scale	95% CI
Placebo	-5.0	—
Tirzepatide MTD	4.4	—

LS Mean difference9.495% CI6.8 – 12.0p<0.001ANCOVA

Secondary/registry result

Change From Baseline in SF 36v2 Acute Form - Physical Functioning Domain Score

Time frame:Baseline (Week 0), Week 88

SF-36 physical

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), T-score	95% CI
Placebo	3.7	—
Tirzepatide MTD	6.3	—

LS Mean difference2.795% CI1.7 – 3.7p<.001ANCOVA

Secondary/registry result

Change From Baseline in IWQOL-Lite-CT - Physical Function Composite Score

Time frame:Baseline (Week 0), Week 88

IWQOL-Lite physical

change from baseline, improvement

Posted result

Group	Value (least_squares_mean), score on a scale	95% CI
Placebo	16.7	—
Tirzepatide MTD	26.0	—

LS Mean difference9.395% CI6.5 – 12.0p<.001ANCOVA

Secondary/protocol endpoint

Change From Randomization in Short Form 36 Version 2 Health Survey (SF 36v2) Acute Form - Physical Functioning Domain Score

Time frame:Randomization (Week 36), Week 88

SF-36 physical

change from baseline, improvement

Secondary/protocol endpoint

Change From Randomization in Impact of Weight on Quality of Life Lite Clinical Trials Version (IWQOL-Lite-CT) - Physical Function Composite Score

Time frame:Randomization (Week 36), Week 88

IWQOL-Lite physical

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in SF 36v2 Acute Form - Physical Functioning Domain Score

Time frame:Baseline (Week 0), Week 88

SF-36 physical

change from baseline, improvement

Secondary/protocol endpoint

Change From Baseline in IWQOL-Lite-CT - Physical Function Composite Score

Time frame:Baseline (Week 0), Week 88

IWQOL-Lite physical

change from baseline, improvement

Publications (9)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.
JAMA network open2026 Mar 2PMID41885866doi:10.1001/jamanetworkopen.2026.3274via clinicaltrials gov reference derived + pubmed nct search
Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials.
Obesity pillars2026 Mar (month)PMID41640675doi:10.1016/j.obpill.2026.100248via clinicaltrials gov reference derived + pubmed nct search
Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
JAMA internal medicine2026 Feb 1PMID41284285doi:10.1001/jamainternmed.2025.6112via clinicaltrials gov reference derived + pubmed nct search
People With Lowest Physical Functioning Scores Showed Greatest Improvement After Tirzepatide Treatment.
Obesity (Silver Spring, Md.)2026 Jan (month)PMID41187013doi:10.1002/oby.70067via clinicaltrials gov reference derived + pubmed nct search
Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4.
Obesity (Silver Spring, Md.)2025 Nov (month)PMID40903801doi:10.1002/oby.70011via clinicaltrials gov reference derived + pubmed nct search
Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.
Obesity (Silver Spring, Md.)2025 Sep (month)PMID40717199doi:10.1002/oby.24348via clinicaltrials gov reference derived + pubmed nct search
Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.
Clinical obesity2025 Jun (month)PMID39800653doi:10.1111/cob.12734via clinicaltrials gov reference derived + pubmed nct search
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA2024 Jan 2PMID38078870doi:10.1001/jama.2023.24945via clinicaltrials gov reference derived + pubmed nct search
Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.
Obesity (Silver Spring, Md.)2023 Jan (month)PMID36478180doi:10.1002/oby.23612via pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.